ArticleCureus2025
Histopathological Insights into Primary Localized Cutaneous Amyloidosis: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Primary Localized Cutaneous Amyloidosis (PLCA) is a rare disorder characterized by amyloid deposition in the skin without systemic involvement. It includes lichen amyloidosis (LA), macular amyloidosis (MA), and biphasic amyloidosis. The pathogenesis is linked to chronic friction, keratinocyte damage, and in some cases, genetic predisposition. Histopathological examination remains the gold standard for diagnosis. Here, we present a series of nine cases of PLCA. Objective This case series aims to establish a correlation between the clinical manifestations of PLCA and the histopathological findings, including special stains, to improve diagnostic accuracy. Identifying these correlations is vital for differentiating PLCA subtypes, guiding treatment strategies, and understanding the underlying pathogenic mechanisms. Methods A retrospective analysis was conducted at Panimalar Medical College and Hospital, Chennai, India, reviewing nine biopsy-confirmed PLCA cases from January 2023 to December 2024. Clinical data, histopathological features, and staining characteristics (hematoxylin & eosin, Congo red, and crystal violet) were analyzed. Results Out of nine cases, LA was the predominant subtype (seven cases), followed by MA (two cases). Female predominance was observed (male-to-female ratio was 1:2), with an age range of 39-65 years. The upper limbs were the most frequently affected site. Pruritus was exclusively seen in LA, while hyperpigmentation was present in all cases. Histopathological analysis revealed amyloid deposits in the papillary dermis, epidermal hyperplasia, and inflammatory infiltration in LA. Congo red staining demonstrated characteristic apple-green birefringence under polarized light, confirming amyloid deposition. Conclusion The study reinforces the clinical and histopathological distinctiveness of PLCA subtypes. LA is strongly associated with chronic friction and pruritus, whereas MA presents with asymptomatic hyperpigmentation. Congo red and crystal violet stains remain indispensable for diagnosis. Despite advances in histopathology, therapeutic options remain limited, necessitating further research into targeted molecular treatments and genetic predispositions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.